Toll Free: 1-888-928-9744

Vitiligo - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vitiligo - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2017, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Vitiligo - Overview Vitiligo - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Vitiligo - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Vitiligo - Companies Involved in Therapeutics Development Aclaris Therapeutics Inc Biocon Ltd Bristol-Myers Squibb Company Celgene Corp Clinuvel Pharmaceuticals Ltd Incyte Corp Vitiligo - Drug Profiles abatacept - Drug Profile Product Description Mechanism Of Action R&D Progress afamelanotide - Drug Profile Product Description Mechanism Of Action R&D Progress apremilast - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-50001 - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-50002 - Drug Profile Product Description Mechanism Of Action R&D Progress itolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress ruxolitinib phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress VLRX-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Vitiligo - Dormant Projects Vitiligo - Product Development Milestones Featured News & Press Releases Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study Dec 03, 2015: Update on North American vitiligo program for SCENESSE May 05, 2015: Clinuvel announces innovative melanocortin for new indications Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo Oct 16, 2012: Observations from Clinuvels US vitiligo study published Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Vitiligo, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Vitiligo - Pipeline by Aclaris Therapeutics Inc, H1 2017 Vitiligo - Pipeline by Biocon Ltd, H1 2017 Vitiligo - Pipeline by Bristol-Myers Squibb Company, H1 2017 Vitiligo - Pipeline by Celgene Corp, H1 2017 Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2017 Vitiligo - Pipeline by Incyte Corp, H1 2017 Vitiligo - Dormant Projects, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify